“Juan Carlos is truly global sense leader, and has been admired by team members and also colleagues. I was very pleased to work for him at either BMS and Abbvie. We have great deal of common sense about proactively development HCV globally particularly in emerging Asia Pacific. His expertise and personal character have been such valuable for team to work out various difficulties. ”
New Haven, Connecticut, United States
Contact Info
1K followers
500+ connections
About
Activity
-
Guadalupe Garcia-Tsao, MD, FRCP, received the 2023 International Mentor Award from the ALEH - Asociación Latinoamericana para el Estudio del Hígado…
Guadalupe Garcia-Tsao, MD, FRCP, received the 2023 International Mentor Award from the ALEH - Asociación Latinoamericana para el Estudio del Hígado…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Michael Curry, MD, Section Chief of Hepatology at Beth Israel Deaconess Medical Center, and Professor of Medicine at Harvard Medical School is…
Michael Curry, MD, Section Chief of Hepatology at Beth Israel Deaconess Medical Center, and Professor of Medicine at Harvard Medical School is…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
I am pleased to announce that Drug Farm has safely dosed healthy volenteer subjects with our first in-class ALPK1 antagonist, DF-003, in a Phase 1…
I am pleased to announce that Drug Farm has safely dosed healthy volenteer subjects with our first in-class ALPK1 antagonist, DF-003, in a Phase 1…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
Experience & Education
Languages
-
English
Native or bilingual proficiency
-
Spanish
Native or bilingual proficiency
-
Catalan
Native or bilingual proficiency
Recommendations received
1 person has recommended Juan Carlos
Join now to viewMore activity by Juan Carlos
-
Day 2 of the #FDA workshop on the use of non-invasive testing (NITs) in NASH/MASH clinical trials! Moving the field forward. Happy to share data on…
Day 2 of the #FDA workshop on the use of non-invasive testing (NITs) in NASH/MASH clinical trials! Moving the field forward. Happy to share data on…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
I am thrilled to announce that the first subject has been dosed with DF-003, our small molecule ALPK1 kinase inhibitor. DF-003 is a first-in-class…
I am thrilled to announce that the first subject has been dosed with DF-003, our small molecule ALPK1 kinase inhibitor. DF-003 is a first-in-class…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
It’s an exciting day for ROME as we announce a financing that will take our lead program through early clinical trials! We’re looking forward to…
It’s an exciting day for ROME as we announce a financing that will take our lead program through early clinical trials! We’re looking forward to…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Continuing our yearly tradition, Dulabh K Monga and I are co-hosting a virtual liver cancer conference organized by Community Liver Alliance and…
Continuing our yearly tradition, Dulabh K Monga and I are co-hosting a virtual liver cancer conference organized by Community Liver Alliance and…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
More data from SOLOIST showing the very large benefit of early SGLT inhibition in patients with #heartfailure. Bertram Pitt Philippe Gabriel Steg…
More data from SOLOIST showing the very large benefit of early SGLT inhibition in patients with #heartfailure. Bertram Pitt Philippe Gabriel Steg…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
I am pleased and excited to announce that I have started a new position in Boston. My new role is as the Director of Clinical Trial Development for…
I am pleased and excited to announce that I have started a new position in Boston. My new role is as the Director of Clinical Trial Development for…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Houston Methodist Hospital has risen in the ranking. We are #5 in the US in GI & our transplant volume has been 2nd and could be #1 soon ;) Proud of…
Houston Methodist Hospital has risen in the ranking. We are #5 in the US in GI & our transplant volume has been 2nd and could be #1 soon ;) Proud of…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Some thoughts about medical therapies to regress and stabilize #coronary plaque by Jairo Aldana-Bitar and with Matthew Budoff. #cardiology #prevention
Some thoughts about medical therapies to regress and stabilize #coronary plaque by Jairo Aldana-Bitar and with Matthew Budoff. #cardiology #prevention
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
BIDMC provides comprehensive liver care for patients with complex liver disease. In addition to our established multidisciplinary programs in liver…
BIDMC provides comprehensive liver care for patients with complex liver disease. In addition to our established multidisciplinary programs in liver…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Cómo puede cambiar casi todo en función de la actitud…
Cómo puede cambiar casi todo en función de la actitud…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
Congratulations to Insmed Incorporated for becoming a certified Great Place to Work in the U.S. for the third year in a row! This is a testament to…
Congratulations to Insmed Incorporated for becoming a certified Great Place to Work in the U.S. for the third year in a row! This is a testament to…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
-
I am delighted to announce the IND Clearance by U.S. FDA for the Phase 1 Initiation of Drug Farm’s First-in-Class Oral ALPK1 Selective Kinase…
I am delighted to announce the IND Clearance by U.S. FDA for the Phase 1 Initiation of Drug Farm’s First-in-Class Oral ALPK1 Selective Kinase…
Liked by Juan Carlos Lopez-Talavera, MD, PhD
Other similar profiles
-
Harith Rajagopalan
Connect -
BARBARA SORONDO, MD MBA
Connect -
Sarah Hackett
Connect -
Emily Sorrentine
Connect -
Emily Cozzi, Ph.D.
Connect -
Imad Asaad
Connect -
Jonca Bull
Vice President at Novartis
Connect -
Michael Tunkelrott
Experienced commercialization executive with global experience in therapeutics and diagnostics.
Connect -
Vikram Kansra
Connect -
Raza Malik MD PhD FRCP FAASLD
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More